Tedizolid Injection Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Tedizolid Injection Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company : MSD
             Kilsheean
             Clonmel Tipperary, IE
   Telephone : 353-51-601000
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   +1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Reproductive toxicity, Category 2
   Specific target organ toxicity - repeated exposure, Category 2
   Short-term (acute) aquatic hazard, Category 1
   Long-term (chronic) aquatic hazard, Category 1
   H361d: Suspected of damaging the unborn child.
   H373: May cause damage to organs through prolonged or repeated exposure.
   H400: Very toxic to aquatic life.
   H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms :
   Signal word : Warning
   Hazard statements :
   H361d  Suspected of damaging the unborn child.
   H373  May cause damage to organs through prolonged or repeated exposure.
   H410  Very toxic to aquatic life with long lasting effects.
Precautionary statements:

**Prevention:**
P201 Obtain special instructions before use.
P260 Do not breathe dust.
P273 Avoid release to the environment.
P280 Wear protective gloves/protective clothing/eye protection/face protection.

**Response:**
P308 + P313 IF exposed or concerned: Get medical advice/attention.
P391 Collect spillage.

Hazardous components which must be listed on the label:
Tedizolid

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tedizolid</td>
<td>856867-55-5</td>
<td></td>
<td></td>
<td>Repr. 2; H361d</td>
<td>&gt;= 50 - &lt; 70</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>STOT RE 2; H373</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(Bone marrow,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Blood, Gastrointestinal tract)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Aquatic Acute 1;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>H400</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Aquatic Chronic 1;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>H410</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>M-Factor (Acute)</td>
<td></td>
</tr>
</tbody>
</table>
SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.
SECTION 5: Firefighting measures

5.1 Extinguishing media
Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides

5.3 Advice for firefighters
Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Personal precautions: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions
Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces
with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types: Strong oxidizing agents
Tedizolid Injection Formulation

7.3 Specific end use(s)
Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tedizolid</td>
<td>856867-55-5</td>
<td>TWA</td>
<td>100 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures
Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection Material : Chemical-resistant gloves

Skin and body protection : Work uniform or laboratory coat.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Equipment should conform to NS EN 143

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical state</td>
<td>(lyophilised)</td>
</tr>
<tr>
<td>Colour</td>
<td>white to off-white</td>
</tr>
<tr>
<td>Odour</td>
<td>odourless</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>May form explosive dust-air mixture during processing, handling or other means.</td>
</tr>
</tbody>
</table>
Tedizolid Injection Formulation

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature, pH</td>
<td>7.4 - 8.1</td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility (solvent)</td>
<td>No data available</td>
</tr>
<tr>
<td>Water solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>No data available</td>
</tr>
<tr>
<td>Particle characteristics</td>
<td>No data available</td>
</tr>
<tr>
<td>Particle size</td>
<td>No data available</td>
</tr>
</tbody>
</table>

9.2 Other information

- Explosives: Not explosive
- Oxidizing properties: The substance or mixture is not classified as oxidizing.
- Evaporation rate: No data available
- Molecular weight: No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.
Tedizolid Injection Formulation

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials
Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
Information on likely routes of exposure :
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:

Tedizolid:
Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg
LD50 (Mouse): > 2.000 mg/kg
Acute toxicity (other routes of administration) : LD50 (Mouse): 256 - 274 mg/kg
Application Route: Intravenous
LD50 (Rat): 244 mg/kg
Application Route: Intravenous
LD50 (Dog): 200 mg/kg
Application Route: Intravenous

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.
Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

Components:

Tedizolid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
Suspected of damaging the unborn child.

Components:

Tedizolid:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, female
Application Route: Oral
Fertility: NOAEL: 15 mg/kg body weight
Result: No effects on fertility

Test Type: Fertility
Species: Rat, male
Application Route: Oral
Fertility: NOAEL: 50 mg/kg body weight
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development
Species: Mouse
Tedizolid Injection Formulation

Application Route: Oral
Developmental Toxicity: LOAEL: 25 mg/kg body weight
Result: Reduced foetal weight, Skeletal malformations

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 15 mg/kg body weight
Result: Reduced foetal weight, Skeletal malformations

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 2,5 mg/kg body weight
Result: Reduced foetal weight, Skeletal malformations

Reproductive toxicity - Assessment: Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:

Tedizolid:
Target Organs: Bone marrow, Blood, Gastrointestinal tract
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Tedizolid:
Species: Rat, female
NOAEL: 10 mg/kg
Application Route: Oral
Exposure time: 28 d
Target Organs: Bone marrow, thymus gland, spleen, Lymph nodes

Species: Rat, male
NOAEL: 30 mg/kg
Application Route: Oral
Exposure time: 28 d
Target Organs: Bone marrow, Lymph nodes, spleen, thymus gland

Species: Rat, female
NOAEL: 15 mg/kg
Application Route: Intravenous
Exposure time: 28 d
Target Organs: Gastrointestinal tract
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Tedizolid Injection Formulation

Version 2.5  Revision Date: 09.04.2021  SDS Number: 657255-00013  Date of last issue: 10.10.2020
Date of first issue: 02.05.2016

11.2 Information on other hazards

Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Tedizolid:
Inhalation: Symptoms: Nausea, Headache, Diarrhoea, Vomiting, Dizziness
Ingestion: Symptoms: Nausea, Headache, Diarrhoea, Vomiting, Dizziness

SECTION 12: Ecological information

12.1 Toxicity

Components:

Tedizolid:
Toxicity to algae/aquatic plants: EC50 (Anabaena flos-aquae): 0.313 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
**Tedizolid Injection Formulation**

**12.2 Persistence and degradability**

**Components:**

**Tedizolid:**

<table>
<thead>
<tr>
<th>Biodegradability</th>
<th>Result: Not readily biodegradable.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biodegradation:</td>
<td>2 %</td>
</tr>
<tr>
<td>Exposure time:</td>
<td>28 d</td>
</tr>
<tr>
<td>Method:</td>
<td>OECD Test Guideline 301B</td>
</tr>
</tbody>
</table>

| Stability in water | Hydrolysis: 0 % (5 d)               |

**12.3 Bioaccumulative potential**

**Components:**

**Tedizolid:**

| Partition coefficient: n-octanol/water | log Pow: 1.3 |

**12.4 Mobility in soil**

**Components:**

**Tedizolid:**

**NOEC (Anabaena flos-aquae):** 0.0632 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

**M-Factor (Acute aquatic toxicity):** 1

**Toxicity to microorganisms:**

<table>
<thead>
<tr>
<th>EC50</th>
<th>&gt; 100 mg/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure time:</td>
<td>3 h</td>
</tr>
<tr>
<td>Test Type:</td>
<td>Respiration inhibition</td>
</tr>
<tr>
<td>Method:</td>
<td>OECD Test Guideline 209</td>
</tr>
</tbody>
</table>

**NOEC:** 100 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

**Toxicity to fish (Chronic toxicity):**

<table>
<thead>
<tr>
<th>NOEC</th>
<th>0.03175 mg/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure time:</td>
<td>32 d</td>
</tr>
<tr>
<td>Species:</td>
<td>Pimephales promelas (fathead minnow)</td>
</tr>
<tr>
<td>Method:</td>
<td>OECD Test Guideline 210</td>
</tr>
</tbody>
</table>

**Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):**

<table>
<thead>
<tr>
<th>NOEC</th>
<th>0.6 mg/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure time:</td>
<td>21 d</td>
</tr>
<tr>
<td>Species:</td>
<td>Daphnia magna (Water flea)</td>
</tr>
</tbody>
</table>

**M-Factor (Chronic aquatic toxicity):** 1
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Tedizolid Injection Formulation

Distribution among environmental compartments: log Koc: 2.6

12.5 Results of PBT and vPvB assessment

Product: Assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

Product: Endocrine disrupting potential
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN: UN 3077
ADR: UN 3077
RID: UN 3077
IMDG: UN 3077
IATA: UN 3077

14.2 UN proper shipping name

ADN: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Tedizolid)
ADR: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Tedizolid)
RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Tedizolid)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Tedizolid)

IATA : Environmentally hazardous substance, solid, n.o.s. (Tedizolid)

14.3 Transport hazard class(es)

ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

**ADN**
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

**ADR**
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

**RID**
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

**IMDG**
Packing group : III
Labels : 9
EmS Code : F-A, S-F

**IATA (Cargo)**
Packing instruction (cargo aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

**IATA (Passenger)**
Packing instruction (passenger aircraft) : 956
Packing instruction (LQ) : Y956
Tedizolid Injection Formulation

Version: 2.5
Revision Date: 09.04.2021
SDS Number: 657255-00013
Date of last issue: 10.10.2020
Date of first issue: 02.05.2016

Packing group: III
Labels: Miscellaneous

14.5 Environmental hazards

ADN
Environmentally hazardous: yes

ADR
Environmentally hazardous: yes

RID
Environmentally hazardous: yes

IMDG
Marine pollutant: yes

IATA (Passenger)
Environmentally hazardous: yes

IATA (Cargo)
Environmentally hazardous: yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable

REACH - List of substances subject to authorisation (Annex XIV): Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable


<table>
<thead>
<tr>
<th>E1</th>
<th>ENVIRONMENTAL HAZARDS</th>
<th>Quantity 1</th>
<th>Quantity 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>100 t</td>
<td>200 t</td>
</tr>
</tbody>
</table>

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Young people under the age of 18 are not allowed to use or be exposed to the product professionally. Young people above the age of 15 are, however, except from this rule if the product is a necessary part of their education.

The components of this product are reported in the following inventories:

- **AICS**: not determined
- **DSL**: not determined
- **IECSC**: not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

### SECTION 16: Other information

#### Full text of H-Statements

- **H361d**: Suspected of damaging the unborn child.
- **H373**: May cause damage to organs through prolonged or repeated exposure.
- **H400**: Very toxic to aquatic life.
- **H410**: Very toxic to aquatic life with long lasting effects.

#### Full text of other abbreviations

- **Aquatic Acute**: Short-term (acute) aquatic hazard
- **Aquatic Chronic**: Long-term (chronic) aquatic hazard
- **Repr.**: Reproductive toxicity
- **STOT RE**: Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Speci-
Tedizolid Injection Formulation

Version 2.5	Revision Date: 09.04.2021	SDS Number: 657255-00013	Date of last issue: 10.10.2020
Date of first issue: 02.05.2016

Further information

Classification of the mixture:

<table>
<thead>
<tr>
<th>Category</th>
<th>Classification</th>
<th>Calculation method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repr. 2</td>
<td>H361d</td>
<td>Calculation method</td>
</tr>
<tr>
<td>STOT RE 2</td>
<td>H373</td>
<td>Calculation method</td>
</tr>
<tr>
<td>Aquatic Acute 1</td>
<td>H400</td>
<td>Calculation method</td>
</tr>
<tr>
<td>Aquatic Chronic 1</td>
<td>H410</td>
<td>Calculation method</td>
</tr>
</tbody>
</table>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NO / EN